Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2361${count})

  • Research Grant, 2015
    Phase IB Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A in Those Who Participated in the AFF008 Program

    Promising Outcomes of Original Grant:
    Accumulation and/or aggregation of alpha-synuclein is central to the pathogenesis of Parkinson’s disease (PD), and its reduction is expected to positively modify...

  • Therapeutic Pipeline Program, 2015
    The Tolerability of Buspirone for the Treatment of Anxiety in Parkinson’s Disease

    Study Rationale:                             
    Anxiety is a common non-motor symptom among individuals with Parkinson’s disease (PD) and is associated with a reduced quality of life. Despite this...

  • Therapeutic Pipeline Program, 2015
    Orexin Receptor Modulators for the Treatment of Circadian Sleep-wake Disorders in Parkinson's Disease

    Study Rationale:
    Reset Therapeutics, Inc. (Reset) will develop a new therapy to address excessive daytime sleepiness, a common non-motor symptom in Parkinson’s disease (PD). The natural daily rhythm of...

  • Access to Data and Biospecimens, 2015
    14-3-3 Phosphorylation as a Biomarker of Parkinson’s Disease Supplement

    Study Rationale:                   
    Disruption of 14-3-3s protein is implicated in Parkinson’s disease (PD). Recently, we observed that 14-3-3 phosphorylation — a chemical modification of 14-3-3s — is...

  • Target Validation, 2015
    Anti-inflammatory Role of Activin-A in Protection against Alpha-synuclein-mediated Pathology

    Objective/Rationale:             
    Neuroinflammation is essential for the pathogenesis and progressionof Parkinson’s disease (PD); therefore, the identification of immunosuppressive agents that can...

  • Improved Biomarkers and Clinical Outcome Measures, 2015
    Eye Tracking as a Biomarker for Manifest and Prodromal Parkinson’s Disease

    Study Rationale:                   
    Over the past 14 years, we have utilized sophisticated commercial eye movement monitoring equipment to collect data from over 3300 participants. Our work aims to...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.